Holen Sie sich die Stockscreener-App
0.5295
2.41%
-0.0131
Handel nachbörslich:
.54
0.0105
+1.98%
Schlusskurs vom Vortag:
$0.5426
Offen:
$0.55
24-Stunden-Volumen:
14.76M
Relative Volume:
2.53
Marktkapitalisierung:
$33.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.1324
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
-71.61%
1M Leistung:
-74.17%
6M Leistung:
-70.25%
1J Leistung:
-77.66%
1-Tages-Spanne:
$0.512
$0.5875
1-Wochen-Bereich:
$0.5005
$1.83
52-Wochen-Spanne:
$0.5005
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Vergleichen Sie OTLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.5295 | 34.79M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy - Investing.com
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy By Investing.com - Investing.com Australia
Largest borrow rate increases among liquid names - TipRanks
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - Quiver Quantitative
FDA rejects Outlook Therapeutics' third BLA submission of bevacizumab for wet AMD - Eyes On Eyecare
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright - Investing.com Canada
Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating - marketscreener.com
OTLK: Chardan Capital Lowers Price Target, Maintains Neutral Rat - GuruFocus
What analysts say about Outlook Therapeutics Inc stockFlag and Pennant Patterns & Double Or Triple Wealth - earlytimes.in
Indegene Limited Included in Top Momentum ScanPortfolio Risk Assessment & Small Investment Big Gains - earlytimes.in
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics - TipRanks
A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Lifecore Biomedical (LFCR) - The Globe and Mail
Outlook Therapeutics price target lowered to $1 from $3 at Chardan - TipRanks
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset - MSN
Outlook Therapeutics plunges 60% as FDA denies Lytenava approval | Tap to know more | Inshorts - Inshorts
Outlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright - TipRanks
Missed window? A third CRL sinks Outlook’s ONS-5010 - BioWorld MedTech
Outlook Left Adrift With Another FDA Rejection For Lytenava - Citeline News & Insights
OTLK: HC Wainwright Maintains Neutral Rating, Lowers Price Targe - GuruFocus
Regulatory tracker: Outlook Therapeutics' ophthalmic bevacizumab hit with another FDA rejection - Fierce Pharma
Outlook Therapeutics shares plunge 61.4% after US FDA declines to approve eye disease drug - marketscreener.com
What analysts say about Outlook Therapeutics Inc 41ON stockSector Leadership Analysis & Small Investment Big Gains - earlytimes.in
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again - Sahm
Why Is Outlook Therapeutics Stock Sinking Friday?Outlook Therapeutics (NASDAQ:OTLK) - Benzinga
FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA - TipRanks
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Outlook Therapeutics Receives FDA Complete Response Letter for ONS-5010 - TradingView — Track All Markets
Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks - Yahoo Finance
Why is Outlook Therapeutics (OTLK) Stock Down 61% in Pre-Market Trading? - TipRanks
Outlook Therapeutics plunges after FDA rejects eye drug for third time - TradingView — Track All Markets
Outlook Therapeutics plunges after rejection from the FDA - medwatch.com
Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus - Benzinga
Outlook Therapeutics shares plunge 61.5% premarket after US FDA declines to approve eye disease drug - marketscreener.com
Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD - Pharmaceutical Technology
VIX Spike: Can Outlook Therapeutics Inc. (41ON) stock resist broad market declines - moha.gov.vn
Apple, Taiwan Semiconductor Manufacturing And 3 Stocks To Watch Heading Into Friday - Benzinga
FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form - Yahoo Finance
Key facts: FDA Rejects Outlook Therapeutics' Lytenava; ONS-5010 Denied Again - TradingView — Track All Markets
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD - ts2.tech
US FDA declines to approve Outlook Therapeutics’ eye disease drug - wibqam.com
Outlook Therapeutics Shares Sink After FDA Issues Another CRL On Wet AMD Therapy - Nasdaq
FDA rejects Outlook Therapeutics’ ONS-5010 eye treatment application By Investing.com - Investing.com Nigeria
Breaking news: FDA sends CRL to Outlook Therapeutics for ONS-5010 resubmission - Optometry Times
Outlook Therapeutics provides regulatory update on U.S. FDA review of Lytenava - marketscreener.com
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA - Ophthalmology Times
US FDA declines to approve Outlook's eye disease drug for second time in 2025 - Reuters
Outlook Therapeutics slides after US FDA declines its eye disease drug - TradingView — Track All Markets
FDA rejects Outlook Therapeutics’ ONS-5010 eye treatment application - Investing.com India
Outlook Therapeutics (OTLK) Shares Plunge After FDA Setback - GuruFocus
Outlook Therapeutics (OTLK) Faces FDA Setback for Wet AMD Treatm - GuruFocus
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):